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Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI)
Background. There are efforts to develop FDA-approved microbiota-based drugs to restore the microbiome, notably for recurrent Clostridium difficile infections (rCDI). Given the lack of established biomarkers for microbiome restoration, we are evaluating unidimensional Microbiome Health Indices (MHI™). We previously presented a prototype MHI for clinical trials of RBX2660-a standardized microbiota restoration therapy in Phase 3 clinical development. Herein we assessed MHI for a published study of fecal microbiota transplant (FMT) for treating rCDI.
Methods. The prototype MHI is based on the associations of Bacteroidia and Clostridia with colonization resistance, and Gammaproteobacteria and Bacilli with dysbiosis, and Receiver Operating Characteristic analysis of pooled RBX2660 trial data indicated that rCDI participants before treatment (baseline) are distinguished from the healthier RBX2660 profile with an odds ratio of 121 (AUC = 0.99, sensitivity = 0.96, specificity = 0.99, cutpoint = 8.2). MHI data for the published FMT cohort were calculated using publicly available data derived from pre-and post-treatment fecal samples (Khanna S, et al. Microbiome 2017 5:55), and this study included patients with or without a co-diagnosis of inflammatory bowel disease (IBD).
Results. At baseline, 92% of patients in the FMT cohort were below the MHI = 8.2 cutpoint, consistent with a rCDI diagnosis. Among FMT responders 7 days after treatment, 91% of patients had shifted to MHI>8.2, (P < 0.0001 compared with baseline). Likewise, a significant shift was observed from baseline to 30 days (P < 0.0001), with 83% having MHI > 8.2. There were insufficient patients to support a statistical comparison of IBD vs. no IBD, but MHIs trended lower at all time points among patients with IBD.
Conclusion. MHI parameters derived from RBX2660 trials were predictive of pre-and post-treatment states for a published cohort of FMT-treated rCDI patients, suggesting that this prototype MHI represents a useful dysbiosis measure beyond RBX2660 trials. Lower MHI among patients co-diagnosed with IBD suggests the potential utility of MHI beyond rCDI. Collectively our results continue to support the utility of MHI and its prospective evaluation in ongoing Phase 3 clinical trials.
Disclosures Background. The MenACYW-TT conjugate vaccine is a quadrivalent meningococcal vaccine candidate intended for global use in all age groups. This pivotal phase II study evaluated the safety and immunogenicity of the vaccine when compared with a licensed quadrivalent conjugated meningococcal vaccine (MCV4-CRM) when co-administered with tetanus, diphtheria, acellular pertussis (Tdap), and human papilloma virus (HPV4) vaccines in meningococcal vaccine naïve adolescents (10-17 years of age).
Methods.
A randomized, open-label, multicenter study (NCT02199691) was conducted in 1,715 healthy subjects in the United States, who were randomly assigned to receive MenACYW-TT conjugate vaccine, MCV4-CRM, MenACYW-TT conjugate vaccine (co-administered with Tdap and HPV4), or Tdap and HPV4 vaccines. Serum bactericidal assay with human (hSBA) and baby rabbit (rSBA) complement was used to measure antibodies against serogroups A, C, W, and Y test strains at baseline and 30 days after vaccination. Safety data were collected up to 6 months post-vaccination.
Results. Noninferiority of immune response was demonstrated between MenACYW-TT conjugate vaccine and MCV4-CRM, and MenACYW-TT conjugate vaccine when co-administered with Tdap and HPV4 vaccines vs. when administered alone, based on percentages of study participants achieving hSBA vaccine seroresponse at Day 30 fromD0 baseline. The proportions of individuals with hSBA ≥ 1:8 after MenACYW-TT conjugate vaccine administration were higher than those after MCV4-CRM administration for all four serogroups (A: 93.5% vs. 82.8%; C: 98.5% vs. 76.0%; W: 99.1% vs. 90.7%; Y: 97.2% vs. 83.2%). Co-administration of MenACYW conjugate, Tdap and HPV4 vaccines did not generate any results suggestive of immune interference. Reactogenicity profiles were comparable across study groups. Most unsolicited adverse events were of Grade 1 or Grade 2 intensity. No vaccine related serious adverse events were reported.
Conclusion. MenACYW-TT conjugate vaccine was immunogenic and well tolerated when administered as a single dose to meningococcal vaccine naïve adolescents along with Tdap and HPV4 vaccines. Such a vaccine will offer an alternative for the prevention of invasive meningococcal disease in susceptible populations across the world.
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